Toward pharmacogenetic SLCO1B1‐guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model
Abstract Low‐dose methotrexate (MTX) is a first‐line therapy for the treatment of arthritis. However, there is considerable interindividual variability in MTX exposure following standard dosing. Polymorphisms in SLCO1B1 significantly effect MTX clearance, altering therapeutic response. One decreased...
Guardado en:
Autores principales: | Zachary L. Taylor, Lauren E. Thompson, Heather Bear, Tomoyuki Mizuno, Alexander A. Vinks, Laura B. Ramsey |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a6b2dde967344193adb79c03c44199eb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p
por: Roberto H. Barbier, et al.
Publicado: (2021) -
A Cost–Consequence Analysis of Preemptive <i>SLCO1B1</i> Testing for Statin Myopathy Risk Compared to Usual Care
por: Charles A. Brunette, et al.
Publicado: (2021) -
Highly expressed SLCO1B3 inhibits the occurrence and development of breast cancer and can be used as a clinical indicator of prognosis
por: Tiantian Tang, et al.
Publicado: (2021) -
SLCO3A1, A novel crohn's disease-associated gene, regulates nf-κB activity and associates with intestinal perforation.
por: Shu-Chen Wei, et al.
Publicado: (2014) -
An EAV-HP insertion in the promoter region of SLCO1B3 has pleiotropic effects on chicken liver metabolism based on the transcriptome and proteome analysis
por: Jianfei Chen, et al.
Publicado: (2021)